New‐onset prediabetes/diabetes worsens overall survival in patients with cancer: A real‐world retrospective cohort study
Improving clinical practice guidelines for appropriate hyperglycemia monitoring and management, especially in the first 3 years after cancer diagnosis, may improve cancer survival. Early intervention with non-insulin antihyperglycemic medications for control of new-onset prediabetes/diabetes may be crucial in preventing the need for insulin prescription and worsening of survival.
Authors
- Richard Viskochil (ORCID: https://orcid.org/0000-0001-7167-174X)
- Mary C. Playdon (ORCID: https://orcid.org/0000-0001-6082-0447)
- Svenja Pauleck
- Prasoona Karra (ORCID: https://orcid.org/0009-0008-5209-9846)
- Sheetal Hardikar (ORCID: https://orcid.org/0000-0003-0292-6168)
- Yizhe Xu (ORCID: https://orcid.org/0000-0002-0773-1709)
- Maci Winn (ORCID: https://orcid.org/0000-0001-7363-0626)
- J.A. Doherty (ORCID: https://orcid.org/0000-0002-9806-9270)
- Stephanie Richardson
- Siwen Hu‐Lieskovan (ORCID: https://orcid.org/0000-0001-5836-4710)
- Michelle L. Litchman (ORCID: https://orcid.org/0000-0002-8928-5748)
- Howard Colman
Institutions
- Dartmouth College (US)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- University of Massachusetts Boston (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1111/dom.70311
- Citations
- 3
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Huntsman Cancer Institute
- National Institutes of Health
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases